- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Journal: Rb Tissue kinetics in humans. (Pubmed Central) - Oct 27, 2021
E is high in kidney and low in spleen and liver. Spleen is erectile, collapsing when perfusion decreases.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT (clinicaltrials.gov) - Oct 26, 2021
P=N/A, N=15, Completed,
Spleen is erectile, collapsing when perfusion decreases. Active, not recruiting --> Completed
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Clinical, Journal: Plasma Lipidomic Patterns in Patients with Symptomatic Coronary Microvascular Dysfunction. (Pubmed Central) - Oct 25, 2021
Subjects (n = 20) aged 35-60 years and referred for computed tomography coronary angiography (CTA) for chest pain but who lacked obstructive CAD (>50% stenosis), underwent quantitative regadenoson stress-rest myocardial contrast echocardiography (MCE) perfusion imaging for MVD assessment...We conclude that specific lipidomic plasma profiles occur in MVD involving saturated long-chain fatty acid-containing acylglycerols that are distinctly different from those in non-obstructive CAD. These patterns could be used to better characterize the pathobiology and potential treatments for this condition.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Clinical, Journal: Cardiac magnetic resonance imaging myocardial perfusion reserve index in heart transplant patients. (Pubmed Central) - Oct 7, 2021
In the absence of epicardial coronary artery disease, patients with heart transplants have lower MPRI than patients without transplants, suggesting microvascular disease. The hemodynamic response to regadenoson is less pronounced in patients with heart transplants than in patients without heart transplants.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment open, Trial completion date, Trial primary completion date: Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System (clinicaltrials.gov) - Oct 4, 2021
P1, N=46, Recruiting,
The hemodynamic response to regadenoson is less pronounced in patients with heart transplants than in patients without heart transplants. Active, not recruiting --> Recruiting | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Jan 2021 --> Jan 2023
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment open, Trial initiation date: Treat COVID-19 Patients With Regadenoson (clinicaltrials.gov) - Oct 3, 2021
P1/2, N=40, Recruiting,
Active, not recruiting --> Recruiting | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Jan 2021 --> Jan 2023 Not yet recruiting --> Recruiting | Initiation date: Nov 2020 --> May 2021
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Management Of Anesthesia In A Patient With History Of Malignant Hyperthermia (Exhibit Hall) - Sep 25, 2021 - Abstract #ASA2021ASA_5035;
Per cardiology, Chest pain described by patient while having stress test likely reflective of Lexiscan side effect...Family hx of Malignant hyperthermia, MHAUS recommendations were followed for anesthesia machine set up and anesthesia was maintained through TIVA. She remained stable throughout the procedure.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Simultaneous Assessment of FFR and SPECT (clinicaltrials.gov) - Sep 17, 2021
P=N/A, N=28, Completed,
The increased HR response may represent a more physiologic assessment of the true vasodilatory capacity remaining in ESLD patients. Recruiting --> Completed | N=50 --> 28 | Trial completion date: Jul 2022 --> Jun 2021 | Trial primary completion date: Dec 2021 --> Dec 2020
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Rings Flying Around: A Rare Complication of Transjugular Intrahepatic Portosystemic Shunt (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_1722;
To further evaluate acute dyspnea, Lexiscan was done which returned negative...Our case highlights the importance of having a broad differential regarding simple bread and butter complaints in the vast field of Internal Medicine. Mechanical complications related to procedures may be rare but present.Figure: Coronal section of CT Chest showing fragmented TIPS stent dislodged and epithelized in pulmonary artery.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Clinical, Journal: Impaired Myocardial Perfusion on Stress CMR Correlates With Invasive FFR in Children With Coronary Anomalies. (Pubmed Central) - Aug 25, 2021
SPECT-MPI using regadenoson is well tolerated in patients with ELD and can help to make decisions about coronary revascularization before lung transplant. Assessment of myocardial perfusion using non-invasive sCMR concurred with FFR, particularly if performed with close proximity in time, and may contribute to risk stratification and decision making in children with AAOCA and/or MB.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion date: Heart Rate Response to Regadenoson and Sudden Cardiac Death (clinicaltrials.gov) - Aug 18, 2021
P=N/A, N=90, Active, not recruiting,
Assessment of myocardial perfusion using non-invasive sCMR concurred with FFR, particularly if performed with close proximity in time, and may contribute to risk stratification and decision making in children with AAOCA and/or MB. Trial completion date: Jun 2021 --> Dec 2021
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Journal: Relationship of Rb PET territorial myocardial asynchrony to arterial stenosis. (Pubmed Central) - Aug 11, 2021
Trial completion date: Jun 2021 --> Dec 2021 Rb PET/CT accurately identified patients with MVD and individual stenosed territories, with regional asynchrony measurements contributing significantly to identify patients with CAD.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Clinical, Journal: A cardiovascular magnetic resonance imaging-based pilot study to assess coronary microvascular disease in COVID-19 patients. (Pubmed Central) - Aug 11, 2021
The CMR protocol comprised cine and late-gadolinium-enhancement (LGE) imaging as well as velocity-encoded (VENC) phase-contrast imaging of the coronary sinus flow (CSF) at rest and during pharmacological stress (maximal vasodilation induced by 400 µg IV regadenoson)...In post-COVID-19 patients with persistent exertional dyspnoea and PVFS, a significantly reduced MPR suggestive of CMD-similar to HCM patients-was observed in the present study. A reduction in MPR can be caused by preceding SARS-CoV-2-associated direct as well as secondary triggered mechanisms leading to diffuse CMD, and may explain ongoing symptoms of exercise dyspnoea and PVFS in some patients after COVID-19 infection.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Journal: Molecular Mechanisms of Adenosine Stress T1 Mapping. (Pubmed Central) - Jul 29, 2021
No abstract available The major findings are that (1) although adenosine myocardial perfusion reserve is mediated through the A receptor, adenosine ΔT1 is mediated through the A and A receptors, (2) adenosine myocardial perfusion reserve is endothelial independent while adenosine ΔT1 is partially endothelial dependent, and (3) ΔT1 mediated through the A receptor is endothelial dependent while ΔT1 mediated through the A receptor is endothelial independent.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Journal: Hemiplegic migraine episode triggered by regadenoson. (Pubmed Central) - Jul 27, 2021
We concluded that regadenoson triggered a hemiplegic migraine episode in this patient, which has not been previously reported in the literature. It may be prudent to avoid regadenoson and adenosine use in patients with a history of hemiplegic migraine.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Journal: Adenosine A2A receptor agonist (regadenoson) in human lung transplantation. (Pubmed Central) - Jul 8, 2021
Regadenoson, an AR agonist, can be safely infused in the setting of lung transplantation with no dose-limiting toxicities or drug-related mortality. Although not powered for the evaluation of secondary end-points, the results of this trial and the outcome of pre-clinical studies warrant further investigation with a Phase II randomized controlled trial.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Clinical, Journal: Assessment of late-term progression of cardiac allograft vasculopathy in patients with orthotopic heart transplantation using quantitative cardiac Rb PET. (Pubmed Central) - Jul 7, 2021
Twenty patients (7 females and 13 males, mean age = 72.7 ± 12.2 years with CAV and 62.9 ± 7.2 years without CAV and post-OHT mean time = 13.9 years), were evaluated retrospectively using dynamic cardiac Rb-PET at rest and regadenoson-induced stress...This study indicates that the resting MBF is higher in late-term post-OHT patients. The high resting MBF and reduced CFR suggest an unprecedented demand of blood flow and blunted response to stress due to impaired vasodilatory capacity that is exacerbated by the presence of CAV.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
[VIRTUAL] Stress myocardial blood flow reduced after severe COVID-19, not related to symptoms () - Jul 6, 2021 - Abstract #ESC2021ESC_2681;
A) Quantitative regadenosone stress myocardial blood flow (MBF) map, medial short axis slice, in a patient with persistent cardiac symptoms after COVID-19. B) Boxplot of stress MBF per heart beat by COVID-19 severity, showing decreasing MBF with increasing COVID-19 severity.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
[VIRTUAL] Regadenoson stress CMR: Safety, feasibility and hemodynamic response. () - Jul 6, 2021 - Abstract #ESC2021ESC_2678;
Conclusions.- The use of regadenoson in stress CMR proved to be safe and feasible in the vast majority of patients. Adverse events were not frequent with regadenoson and symptoms were transient and well tolerated, while premature ending of the test related to drug administration was very rare.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment change: Stress Testing and Cardiac Magnetic Resonance (clinicaltrials.gov) - Jun 29, 2021
P4, N=20, Completed,
Adverse events were not frequent with regadenoson and symptoms were transient and well tolerated, while premature ending of the test related to drug administration was very rare. N=114 --> 20
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment open, Trial completion date, Trial primary completion date: The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI (clinicaltrials.gov) - Jun 29, 2021
P=N/A, N=30, Recruiting,
N=114 --> 20 Not yet recruiting --> Recruiting | Trial completion date: Sep 2021 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Dec 2022
- |||||||||| Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
Journal: Pituitary apoplexy after regadenoson myocardial perfusion scan. (Pubmed Central) - Jun 23, 2021
Not yet recruiting --> Recruiting | Trial completion date: Sep 2021 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Dec 2022 No abstract available
- |||||||||| Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
Journal: A permeable on-chip microvasculature for assessing the transport of macromolecules and polymeric nanoconstructs. (Pubmed Central) - Jun 22, 2021
The vascular compartment was coated by endothelial cells to achieve permeability values ranging from ~0.1 μm/sec, following a cyclic adenosine monophosphate (cAMP) pre-treatment (25 μg/mL), up to ~2 μm/sec, upon exposure to Mannitol, Lexiscan or in the absence of cells...In the presence of a continuous endothelium, soft DPN attached to the vasculature more avidly at sub-physiological flows (100 μm/sec) than rigid DPN, whose deposition was larger at higher flow rates (1 mm/sec). The proposed double-channel microfluidic device can be efficiently used to systematically analyze the vascular behavior of drug delivery systems to enhance their tissue specific accumulation.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion date, Trial primary completion date: Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking (clinicaltrials.gov) - Jun 11, 2021
P4, N=300, Active, not recruiting,
The proposed double-channel microfluidic device can be efficiently used to systematically analyze the vascular behavior of drug delivery systems to enhance their tissue specific accumulation. Trial completion date: Aug 2021 --> Aug 2023 | Trial primary completion date: Aug 2020 --> Aug 2022
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion, Enrollment change: Stress Testing and Cardiac Magnetic Resonance (clinicaltrials.gov) - May 21, 2021
P4, N=114, Completed,
Regadenoson stress and rest T1-mapping is a viable alternative to adenosine and exercise for the assessment of CAD and can distinguish between normal, ischemic, infarcted, and remote myocardium. Recruiting --> Completed | N=525 --> 114
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Journal: Quantitative 3D myocardial perfusion with an efficient arterial input function. (Pubmed Central) - May 15, 2021
This work demonstrates that a quantitative 3D myocardial perfusion sequence with the acquisition of a 2D arterial input function is feasible at high stress heart rates such as during stress. T1 values and gadolinium concentrations of the sequence match the reference standard well in a phantom, and myocardial rest and stress perfusion and myocardial perfusion reserve values are consistent with those published in literature.
- |||||||||| Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
Clinical, Journal: Safety of regadenoson for vasodilation in cardiac MRI stress tests. (Pubmed Central) - May 11, 2021
T1 values and gadolinium concentrations of the sequence match the reference standard well in a phantom, and myocardial rest and stress perfusion and myocardial perfusion reserve values are consistent with those published in literature. Regadenoson is well tolerated and can be safely used for cardiac MRI stress tests.
- |||||||||| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion date, Trial primary completion date: Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics (clinicaltrials.gov) - Apr 30, 2021
P=N/A, N=68, Active, not recruiting,
Regadenoson is well tolerated and can be safely used for cardiac MRI stress tests. Trial completion date: Jun 2019 --> Jun 2022 | Trial primary completion date: Jun 2019 --> Jun 2022
|
